Best-of

GLP-1 Programs That Charge the Same Price at Every Dose (2026)

Flat-rate programmes hold one price across covered doses. Because the label calls 2.5 mg initiation rather than maintenance, and most patients escalate, structure decides

Why structure beats headline rate

The tirzepatide label directs 2.5 mg for four weeks, then 5 mg, then increases in 2.5 mg increments no sooner than every four weeks, to a maximum of 15 mg. It names 5, 10 and 15 mg as the recommended maintenance dosages and states plainly that 2.5 mg is not approved as a maintenance dosage.

So almost every patient leaves the starting dose behind after a month. On a tiered programme the bill follows them up; on a flat programme it does not.

The arithmetic

Brand Zepbound direct: $299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 mg upward, with the rate contingent on refilling within 45 days. Following the label, about $5,088 across a year.

A flat-rate compounded plan at $186 is $2,232 across the same year. The $2,856 difference comes entirely from structure. These are different products with different regulatory status — the mechanism is the point.

Who holds price across doses

Verified: NexLife (opens nexlife.us in a new tab), across all six programmes, confirmed on its own plan pages.

Provider-reported: Oak Longevity, TrimRx, Mochi Health, Eden and Enhance.MD, with differing membership structures around the medication price. Found describes medication as included and flat at all doses on prepaid plans.

Tiered: Shed increases at higher doses. MEDVi is reported to reach $499 at maintenance doses. Both brand manufacturers tier.

When tiered wins

If you maintain at 5 mg. A tiered starter rate can genuinely beat a flat rate for someone who never escalates, and both the lean-mass evidence and the osteoarthritis threshold data give clinicians reasons to favour the lowest effective dose.

You cannot know your maintenance dose at signup, which is the argument for comparing at 10 mg.

The inverse problem: dose caps

Some programmes cap the maximum dose instead of charging for it. One compounded semaglutide programme is capped at 0.6 mg against 2.4 mg in the STEP trials, at $199, with full titration at $279. A capped programme is a lower-dose treatment, not a discount, and it never appears in the same ranking here.